| EN

RUIANTUO:Cinacalcet Hydrochloride Tablets

RUIANTUO:Cinacalcet Hydrochloride Tablets

Indications:

for the treatment of secondary hyperparathyroidism (SHPT) in  maintenance dialysis patients with chronic kidney disease (CKD).

Cinacalcet (calcimimetic) inhibits the secretion of parathyroid hormone by binding to the transmembrane domain of calcium receptors on the surface of parathyroid cells and transferring calcimimetic signals to the cells. It is currently the only calcimimetic that significantly lowers PTH/calcium/phosphorus/calcium-phosphorus product in China, and is the first-line drug recommended by a number of domestic and foreign guidelines (2017 version of KDIGO guideline, 2019 version of China CKD-MBD guideline).